Saniona hosts research and development (R&D) day for proprietary ion channel drug discovery engine and pipeline program

[ad_1]

Press release

may 20, 2021

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company focused on rare diseases, announced today that it Escrow Virtual R&D Day eventDuring this period, it discussed its ion channel drug discovery engine and proprietary IONBASE™ database. The company also provided data on its ion channel pipeline programs SAN711 and SAN903.

A replay of the event can be found under “Events and Demos” in the “Investors” section of the Saniona website, and here: https://media.rampard.com/20210520/.

Rami Levin, President and CEO of Saniona, said: “Our industry-leading ion channel drug discovery engine allows us to create a wide variety of highly selective compounds, which may meet the unmet needs of various diseases.” “We are very pleased. Introducing our proprietary technology and providing new details about preclinical drug candidates SAN711 and SAN903, which proves the ability of our discovery engine to generate stable sources of preclinical drug candidates, which are rapidly entering the clinic.”

Saniona’s ion channel drug discovery engine combines internal expertise in chemistry, precision biology, in vivo stability/distribution, target participation, in vivo pharmacology and artificial intelligence to accelerate the detection of highly selective, subtype and state-dependent ions Discovery. Channel modulator. The core of the engine is Saniona’s proprietary IONBASE database, which contains structure activity data of more than 120,000 compounds. Among them, 20,000 are Saniona’s proprietary compounds. After 20 years of production, their content has been optimized to achieve the best ion channel adjustment.

SAN711 is a first-class drug candidate that can selectively enhance the effect of GABA-A on α3-containing receptors. This selectivity is very suitable for rare neurological diseases and can enable SAN711 to avoid the typical adverse reactions associated with non-selective GABA-A activation, such as sedation, motor instability, cognitive impairment, abuse of responsibility and physical dependence. During the R&D day event, Saniona provided pre-clinical data to prove the efficacy of the product. in vivo Trigeminal neuralgia model, a rare form of neuropathic pain. After acute medication, SAN711 relieves pain in a dose-dependent manner. The highest dose can relieve pain. Similar to the standard of care for carbamazepine, carbamazepine has many serious side effects. After long-term administration, SAN711 has been proven to prevent the development of pain and maintain long-term efficacy. In another preclinical model of chronic pain, SAN711 was compared with morphine. SAN711 still maintained its efficacy 7 days after administration, but due to the tolerance during the same period, the initial efficacy of morphine was completely eliminated. Data comparing SAN711 with the non-selective GABA-A activator diazepa showed that SAN711 did not induce the sedative effect of diazeppa. Saniona expects that SAN711 will enter the Phase 1 study of healthy volunteers in mid-2021, with data expected in early 2022.

SAN903 is a new type of inhibitor of calcium-activated potassium channel KCa3.1 and is currently under development for the treatment of rare inflammatory and fibrotic diseases. The data provided during the “R&D Day” event proved the efficacy of SAN903 in a variety of in vivo and in vitro models of inflammation and fibrosis. Recent data provided at the American Society of Pharmacology and Experimental Therapeutics (ASPET) annual meeting in 2021 in Experimental Biology (EB) shows that SAN903 can reduce inflammation and fibrosis more effectively than two commercially available products, nintedanib and pirfenidone. in vivo A model of idiopathic pulmonary fibrosis. Saniona expects to start a phase one study to evaluate SAN903 in healthy volunteers by mid-2022.

For more information, please contact
Trista Morrison, Chief Communications Officer of Saniona. Office: +1 (781) 810-9227. e-mail: trista.morrison@saniona.com

The information has been submitted for publication through the agency of the above-mentioned contact. 20.30 Open at CEST may 20, 2021.

About Sannion
Saniona is a biopharmaceutical company dedicated to discovering, developing and providing innovative treatments for patients with rare diseases around the world. The company’s main product candidate, Tesomet, is undergoing mid-term clinical trials for hypothalamic obesity and Prader-Willi syndrome, which is a serious rare disease with uncontrollable hunger and uncontrollable weight gain As a feature. Saniona’s powerful drug discovery engine has established a library that now consists of more than 20,000 proprietary modulators of ion channels, a scientifically validated drug category that is underutilized. The candidate drug candidate SAN711 is entering the first stage of rare neuropathic diseases, and SAN903 for rare inflammatory and fibrotic diseases will be developed through preclinical development. Under the leadership of an experienced scientific and operational team, Saniona has an established research institute in Copenhagen, Denmark, and a corporate office in the Boston area of ​​Massachusetts, USA. The company’s stock is listed on the NASDAQ Stockholm Small Stocks (OMX: SANION).Learn more about www.saniona.com.

Main logo

[ad_2]

Source link